HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Hiromi Wada Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tanaka, F. Articles by Wada, H. Search for Related Content PubMed PubMed Citation Articles by Tanaka, F. Articles by Wada, H.

Eur J Cardiothorac Surg 1999;14:256-262
© 1999 Elsevier Science NL

Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)¹

Department of Thoracic Surgery, Chest Disease Research Institute, Kyoto University, Shogoinn-kawahara-cho 53, Sakyo-ku, Kyoto 606, Japan

Received 29 September 1997; received in revised form 20 April 1998; accepted 13 May 1998.

Corresponding author. Tel.: +81 75 7513835; fax: +81 75 7514647

Objective: Although adjuvant therapy after surgery for non-small cell lung cancer (NSCLC) has been reported to be ineffective, it has been recently reported in prospective randomised studies conducted by two different groups in Japan that oral administration of a 5-fluorouracil (5-FU) derivative drug, UFT (a combination drug of tegafur and uracil) can improve the post-operative survival [The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eu J Surg Oncol 1995;21:69–77; Wada, H., Hitomi, S., Teramatsu, T, West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 1996;14:1048–1054]. To examine the efficacy of UFT as post-operative adjuvant therapy, a retrospective study was performed. Methods: A total of 655 consecutive patients who underwent complete tumor resection for pathologic stage I-IIIa, NSCLC at the Department of Thoracic Surgery, Chest Disease Research Institute, Kyoto University between 1976 and 1992 were retrospectively reviewed. As post-operative adjuvant therapy, UFT was administrated to 98 patients (UFT group), and was not administered to the other 557 patients (Control group). Results: The 5-year survival rate of the UFT group was 76.5%, which was significantly better than that of the Control group (5-year survival rate: 58.6%, P=0.005). Stratified with pathologic stage, the efficacy of UFT was seen in the p-stage I disease (5-year survival rate: 88.6% for the UFT group, 72.0% for the Control group, P=0.013) and in the p-stage IIIa, pN2 disease (5-year survival rate: 54.3% for the UFT group, 37.5% for the Control group, P=0.037). Multivariate analysis of the prognostic factors also revealed the efficacy of UFT (P=0.004, 95% confidence interval of relative risk: 0.325–0.840). Post-operative intravenous chemotherapy or radiation therapy did not prove to be significant factors affecting the prognosis. Conclusions: Efficacy of oral administration of UFT as post-operative adjuvant therapy for completely resected NSCLC was proposed. To confirm the efficacy, a prospective randomized study for a more homogenous patient group is needed.

Key Words: Lung cancer • Non-small cell • Surgery Adjuvant therapy • UFT • 5-fluorouracil

This article has been cited by other articles:

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				F. Tanaka, K. Yanagihara, Y. Otake, T. Yamada, T. Shoji, R. Miyahara, K. Inui, and H. Wada Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC) Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 555 - 561. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and K. Kelly New Combinations in the Treatment of Lung Cancer : A Time for Optimism Chest, April 1, 2000; 117(4_suppl_1): 138S - 143S. [Abstract] [Full Text] [PDF]